Feb 5, 2026
what are cost-benefit ratios of prescibing habitRibociclib, palbociclib and abemaciclib IN uk
Published -focused economic models repeatedly find to be both cheaper and more effective than palbociclib in first‑line HR+/HER2− advanced breast cancer, with multiple analyses also estimating ribocic...